From 1981 to 2000, a total of 1823 children with acute myeloid leukemia (AML) enrolled on four consecutive Pediatric Oncology Group (POG) clinical trials. POG 8101 demonstrated that the induction rate associated with the 3 þ 7 þ 7 combination of daunorubicin, Ara-C, and 6-thioguanine (DAT) was greater than that associated with an induction regimen used to treat acute lymphoblastic leukemia (82 vs 61%; P ¼ 0.02). Designed as a pilot study to determine the feasibility of administration of noncross-resistant drug pairs and later modified to assess the effect of dose intensification of Ara-C during the second induction course, POG 8498 confirmed the high initial rate of response to DAT (84.2%) and showed that dose intensification of Ara-C during the second induction course resulted in a trend toward higher event-free survival (EFS) estimates than did standard-dose DAT (2 þ 5) during the second induction course (5 year EFS estimates, 22 vs 27%; P ¼ 0.33). Age o2 years and leukocyte count o100 000/mm 3 emerged as significantly good prognostic factors. The most significant observation made in the POG 8498 study was the markedly superior outcome of children with Down's syndrome who were treated on the high-dose Ara-C regimen. POG 8821 compared the efficacy of autologous bone marrow transplantation (BMT) with that of intensive consolidation chemotherapy. Intent-to-treat analysis revealed similar 5-year EFS estimates for the group that underwent autologous BMT (3674.7%) and for the group that received only intensive chemotherapy (3574.5%) (P ¼ 0.25). There was a high rate of treatment-related mortality in the autologous transplantation group. The study demonstrated superior results of allogeneic BMT for patients with histocompatible related donors (5-year EFS estimate 6375.4%) and of children with Down's syndrome (5-year EFS estimate, 6678.6%). The POG 9421 AML study evaluated high-dose Ara-C as part of the first induction course and the use of the multidrug resistance modulator cyclosporine. Preliminary results showed that patients receiving both highdose Ara-C for remission induction and the MDR modulator for consolidation had a superior outcome (5-year EFS estimate, 4278.2%) than did patients receiving other treatment; however, the difference was not statistically significant. These four studies demonstrate the importance of dose intensification of Ara-C in the treatment of childhood AML; cytogenetics as the single most prognostic factor and the unique curability of AML in children with Down's syndrome.
Introduction
The general focus of the Pediatric Oncology Group (POG) acute myeloid leukemia (AML) studies was to explore the use of cytarabine dose intensification in the treatment for childhood AML. In this paper, we review four successive POG AML studies in which a stepwise dose intensification of cytarabine was introduced along with anthracyclines. During these studies, we also evaluated the role of autologous and allogeneic bone marrow transplantation (BMT) in first remission in the treatment of childhood AML. Further centralized, morphology review immunophenotyping and cytogenetic evaluation was incorporated in successive, thus allowing for evaluation of prognostic features in large cohorts of childhood AML cases.
Since 1981, four consecutive AML trials have been performed by the POG. Table 1 gives an overview of the number of centers involved in three of the four trials, the average numbers of patients, and the distribution of patients by age at diagnosis.
Before 1981, patients with AML were treated with regimens similar to those used to treat childhood acute lymphoblastic leukemia (ALL), and the results of the AML treatment were relatively poor. Clinical trials of more intensive regimens consisting of cytarabine (Ara-C) and anthracycline started with the POG 8101 study. [1] [2] [3] In POG 8101 patients were randomly assigned to receive either the 3 þ 7 þ 7 regimen of DAT (daunorubicin, Ara-C, and 6-thioguinine) or a regimen that had been used to treat ALL and included vincristine, dexamethasone, and Ara-C. The therapy given after remission induction included a long maintenance phase given over 2 years.
The POG 8498 pilot study evaluated the efficacy and toxicity of high-dose Ara-C given both as a second induction course after DAT and as consolidation therapy immediately after the completion of remission induction therapy. Multiagent chemotherapy after remission induction was modeled after the VAPA regimen of Weinstein et al. 4 The results clearly confirmed the efficacy of the DAT regimen as part of initial induction therapy and established a toxicity profile for high-dose Ara-C in childhood AML. 4 In addition, the immunophenotypic characteristics of childhood AML were analyzed in detail. 5 Finally, the superior outcome of children with Down's syndrome treated on high-dose Ara-C-containing regimens was first recognized.
to allogeneic BMT. 7 The outcome of patients who underwent autologous BMT as given in this study was not superior to that of patients who received only intensive chemotherapy. 7 The POG 9421 study compared the results of treatment using standard-dose DAT as a first induction course with those of treatment using high-dose Ara-C (1 g/m 2 per dose; total, 14 doses), daunorubicin (45 mg/m 2 daily for 3 days), and 6-thioguanine (for 7 days) given as a first induction course. The safety and efficacy of an MDR modulator administered during intensification therapy was also investigated. Preliminary results of this trial are presented in this paper.
Patients and methods

Eligibility
The main entry criteria of studies 8101, 8498, and 8821 were age p21 years and previously untreated AML (patients with secondary AML were eligible if the treatment was for another type of malignancy); patients with an isolated chloroma were eligible. Patients with myelodysplastic syndrome were not eligible, and starting with the POG 8498 study, data of patients with Down's syndrome were analyzed separately from those of the other patient groups.
For POG 9421, patients with APL were not eligible, and patients with Down's syndrome were not eligible for random assignment to the groups that received high-dose DAT or cyclosporine (CsA); instead, patients with Down's syndrome were treated with the standard chemotherapy regimen.
Diagnosis
Standard French-American-British (FAB) criteria were used in the initial diagnosis of AML and its subtypes. Central pathology review occurred in all studies. Diagnosis of M0 and M7 subtypes required confirmation by immunologic methods. The day-14 bone marrow aspirates were reviewed locally.
Treatment
The treatments are shown schematically in Figure 1 . The drug doses are summarized in Table 2 . Table 1 Accrual and follow-up of all patients (M1 + M2a <15% blasts) Randomize VP/AZ VP/AZ DAT DAT HdA 6 HdA 6 D+ Chemo = VP/AZ VP/AZ DAT DAT HdA 6 HdA 6 D+ Chemo = VP/AZ VP/AZ DAT DAT HdA 6 HdA 6 D+ VP/AZ VP/AZ DAT DAT HdA 6 HdA 6 HdA 6 HdA 6 D+ Chemo = * = IT ara-c X 2 Treatment schema of three consecutive POG AML studies. (a) Treatment schema of the POG 8101 and 8498 studies. In POG 8101, patients assigned to group II Received the 3 þ 7 regimen of DAT, whereas patients in group I received a regimen designed originally to treat ALL (not shown???). In POG 8498, patients were assigned randomly to either group I (8498-I) or group II (8498-II). Pediatric Oncology Group studies of acute myeloid leukemia Y Ravindranath et al High-dose Ara-C for consolidation 48 000
Pediatric Oncology Group studies of acute myeloid leukemia Y Ravindranath et al 8821 studies, the first course of remission induction therapy was the DAT regimen. The difference in induction therapy between 8498 and 8821 was the introduction of high-dose Ara-C as a second induction course for Group II patients (see next paragraph) on 8498 and for all patients on POG 8821. In POG 9421, the major change was the administration of highdose Ara-C as part of the DAT regimen given as the first induction course to a particular group of patients.
In POG 9421 for remission induction patients who were assigned randomly to standard DAT therapy (treatments 1, 2, and 5) in the POG 9421 trial received Ara-C (100 mg/m 2 per day) by continuous infusion for seven consecutive days (total, 168 h); daunomycin (45 mg/m 2 per day) by intravenous infusion over 15 min on days 1-3; and thioguanine (100 mg/m 2 per day) orally for 7 days. Patients assigned randomly to the HDAT group (treatments 3 and 4) received identical doses of daunomycin and thioguanine, but Ara-C 
Local radiotherapy permitted for patients with CNS or extra-cranial mass lesions
Autologous bone marrow transplantation: Patients to undergo autologous BMT must have been in complete remission after consolidation course of etoposide and azacytidine, and be free of disseminated fungal disease.
Marrow harvesting: patient's bone marrow is harvested 6-12 weeks after the start of etoposide and azacytidine. To eliminate myeloblasts, the harvested marrow is treated under sterile conditions for 30-min with perfosfamide (4-hydroperoxycyclophosphamide) at a concentration of 100 mg/ml, and an incubation hematocrit of 5-10%.
Preparative regimen: patients receive busulfan 4 mg/ m 2 /day, orally, every 6-h, on days 9, 8, 7, and 6 BEFORE transplantation; and, cyclophosphamide 50 mg/kg, i.v., days 5, 4, 3, and 2 BEFORE transplantation.
Infusion of marrow: after 1 day of REST, the cryopreserved marrow is thawed and infused, on day 0. All patients receive phenytoin, on days 11-4 BEFORE transplantation, as prophylaxis against seizures.
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(1 g/m 2 per dose) was administered as a 1-h infusion every 12 h for 7 consecutive days.
Post-induction therapy:
In POG 8101 patients after remission induction all patients received cranial radiation (age adjusted 1500-2400 cGy) and consolidation therapy with thioguanine (Tg; days 1-4), Ara-C (days 5, 6) and azacytidine (Az; days 7, 8) . Patients were then randomized to 2 years of maintenance therapy: arm 1-two cycle maintenance (cycle 1 ¼ AraC/Tg; cycle 2 ¼ vincristine[Vcr]/Ara-C/cyclophosphamide [Cy]/prednisone [pred]) or arm 2-four cycle maintenance (DNR/Ara-C; Ara-C/Tg; Tg/Ara-C/Az and Vcr/Ara-C/Cy/Pred).
In the first phase of POG 8498, 4 the second course of induction therapy was a 2 þ 5 þ 5 combination of DAT. Patients in Group I received postremission induction therapy consisting of high-dose Ara-C (3 g/m 2 , four doses) and L-asparaginase given monthly for four courses followed by etoposide given once every 4 weeks for four courses; the classic POMP regimen (prednisone given on days 1-5, vincristine given on day 1, methotrexate given intravenously on days 1-5, and 6-mercaptopurine given intravenously on days 1-5); and finally Ara-C alone (200 mg/m 2 given by continuous infusion on days 1-5) for four courses. In the second phase (Group II), instead of DAT (2 þ 5 þ 5), high-dose Ara-C (total, six doses) and L-asparaginase was administered as the second induction course; the postremission therapy of Group II was same as that administered to Group I.
In POG 8821 trial, 7 for postremission therapy patients were randomly assigned to chemotherapy or autologous BMT, patients with matched family donors were eligible for allogeneic BMT. The patients assigned to the chemotherapy group received multidrug consolidation courses. The patients who underwent autologous BMT had bone marrow harvested after recovery from the first course of etoposide/azacytidine (VP/AZ) therapy; the harvested marrow was purged by treatment with 4-hydroxycyclophosphamide at a concentration of 100 mg/ml and an incubation hematocrit of 5-10%; the patients were prepared for autologous BMT by treatment with a standard busulphan/cyclophosphamide regimen. The study was amended in 1990 (with approval from the data monitoring committee) to exclude the randomized assignment of children with Down's syndrome to groups that undergo allogeneic BMT or autologous BMT.
In POG 9421, patients without matched related donors received three courses of consolidation chemotherapy. Assignment to the group that received consolidation therapy (consolidation courses I and III) was accomplished by 2 Â 2 randomization at initial diagnosis to stratified standard and cyclosporine A (CsA)-containing arms. Consolidation course II was the same for all patients. Patients assigned randomly to standard treatment arms in POG 9421 received etoposide (100 mg/m 2 ) as a daily 1-h infusion for 5 days, mitoxantrone (10 mg/m 2 ) as a daily 30-min infusion on days 1-4, and Ara-C (40 mg/m 2 ) intrathecally on day 1. With appropriate hydration and antiemetic therapy, this therapy was administered on an outpatient basis in some cases. Patients assigned randomly to CsA treatment arms received continuous-infusion CsA with modified doses of etoposide (60 mg/m 2 per day) given by 1-h infusion for 5 days and mitoxantrone (6 mg/m 2 daily) given as a daily 30-min infusion on days 1-4. These doses were 60% of the standard dose, and the reduction was based on pharmacokinetic data that demonstrated that the clearance of etoposide and mitoxantrone was reduced by 40% when both agents were administered with high doses of CsA. 8 Administration of etoposide and mitoxantrone at 60% of standard doses with CsA was expected to result in myelotoxicity similar to that observed when standard doses of the two are given without an MDR1-modulating agent.
CNS therapy: Cranial radiation therapy was given to all patients in POG 8101 but not to all patients in studies 8498, 8821, and 9421. In these three latter studies, patients with chloromas were permitted to receive radiation therapy, and lowdose cranial irradiation was permitted for patients with CNS leukostasis. In POG 8498, central nervous system (CNS) prophylaxis consisted of Ara-C administered intrathecally on days 1 and 7 of course 1 of induction day 1 of the first two courses of VP/AZ therapy and on day 1 of the first and second courses of the POMP regimen (total number of doses, 6). To patients with CNS disease at diagnosis, two additional doses were given intrathecally on days 13 and 22 of the first induction course.
Definitions and statistics
Complete remission was defined as less than 5% blast cells in the marrow after the second course of induction therapy.
Patients with M2A marrow (5-25% blast cells) after the second course of induction therapy proceeded to the next phase of therapy, but their disease had to be in complete remission after the completion of the third course of induction therapy before consolidation therapy could begin. Event-free survival (EFS) was calculated from the date of registration to the date of last follow-up or first event (failure to achieve remission, resistant leukemia, relapse in any site, second malignancy, or death due to any cause). Overall survival (OS) was based on the length of time until death. The date of registration marked the beginning of EFS and OS for the entire group; the date of remission marked the beginning of diseasefree survival (DFS). Actuarial curves showing EFS and OS estimates and DFS estimates were constructed according to the Kaplan-Meier method. The relative risks were estimated by using the Cox proportional hazard's model. The association of covariates and response was tested by the logistic regression method. Differences in EFS and OS between two or more groups were tested for statistical significance by the log rank test according to the intention-to-treat principle. The homogeneity of proportion was tested by the w 2 test. For the partitioning analysis, the covariates were analyzed by univariate methods and by the recursive partitioning and amalgamation methods to assess their degree of association with EFS. The partitioning and amalgamation analysis is based on Cox's regression model that includes three independent variables, an indicator for one of the binary covariates and two time-dependent treatment indicators. Details are described in the publication by Chang et al. 9 All reported P-values are two-sided.
Results
Initial features of patients enrolled on POG 8101, 8498, and 8821
Patient characteristics, FAB phenotype, and cytogenetic features are shown in Table 3a and b. Table 3a gives data of all patients except those with Down's syndrome. Table 3b shows data of patients younger than 15 years. Figure 4 .
Early Deaths: The rate of early death (ie, death during induction therapy) remained relatively constant in studies 8101, 8498, and 8821 (Table 4a and b). The nonresponse rate was slightly high in POG 8101, primarily for patients randomly assigned to the vincristine, Ara-C, and dexamethasone arm. As noted in the primary publication about POG 8101, the randomization between the vincristine, Ara-C, and dexamethasone arm and the DAT arm was stopped once the early results identified the relatively poor outcome of patients who received the standard type of induction therapy used to treat ALL (61 vs 82%; P ¼ 0.02).
Deaths in remission (see Table 4a .8) s.e., standard error.
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Trends in patients undergoing BMT:
The number of children undergoing allogeneic BMT in POG 8821 was twice that of patients undergoing the same procedure in POG 8101 and 8498; this increase reflects the changing practice of early allogeneic BMT during first remission of AML in the United States. Since the POG 8821 study was among the first studies to systematically require early evaluation of all registered patients to determine whether they were eligible for allogeneic BMT, the proportion of AML patients to undergo allogeneic BMT in this study (13.7%) reflects the current proportion of children with AML that eventually proceed to matched donor BMT in the United States.
Distinct results of POG 8101
The POG 8101 study established that in childhood AML a 3 þ 7 þ 7 combination of anthracyclines, Ara-C, and 6-TG yields rates of remission induction and EFS that are superior to those generated by the use of an induction regimen originally designed to treat ALL. The complete remission rate associated with DAT was superior (82 vs 61%; P ¼ .02). Overall, the DFS estimates after remission for the best combination of induction and continuation therapy combination (DAT induction and four cycle maintenance) were 32% at 3 years and 29% at 5 years.
Distinct results of POG 8498
The POG 8498 trial established the feasibility of administering high-dose Ara-C during the second induction course and intensification. 4 There was no cerebellar toxicity associated with the four-dose schedule of high-dose Ara-C (3 g/m 2 per dose), whereas acute cerebellar toxicity was noted in three of the 174 courses of high-dose Ara-C therapy (3 g/m 2 ; total number of doses 6) given to 113 patients. The outcome associated with the use of high-dose Ara-C as a second course of induction therapy was slightly better than that associated with the use of standard DAT as a second course, but the difference was not significant (5-year EFS estimates, 27 vs 22%;
Another important finding of this study was the identification for the first time of the superior outcome of children with Down's syndrome; all 14 children with Down's syndrome treated on this protocol are alive and free of disease at the time that the original paper describing this finding was written. 6 Further this study included the first comprehensive review of immunophenotying in childhood AML; the results demonstrated the reliability of expression of CD33 and CD13 for immunophenotypic diagnosis of AML. 5 The study also showed that blast cells from a large proportion of patients with AML (61%) expressed at least one lymphoid-associated antigen, most commonly CD4, CD7, or CD19; acute promyelocytic leukemia blasts lacked CD34 and that the expression of CD14 was positively correlated with FAB M4 or M5 morphology. Figure 2 Overall survival probabilities of all patients enrolled on POG 8101, POG 8498, and POG 8821. Overall survival probabilities (a) and event-free survival probabilities (b) of patients younger than 15 years enrolled on POG 8101, POG 8498, and POG 8821. Overall survival probabilities (a) and event-free survival probabilities (b) of patients 15 years of age or older enrolled on POG 8101, POG 8498, and POG 8821.
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Distinct results of POG 8821
The primary aim of the POG 8821 study was to compare the safety and efficacy of autologous BMT early in first remission with those of intensive chemotherapy. The study identified several practical issues related to the conduct of a randomized multi-institutional study of autologous BMT for children with AML. For example, 38% of the patients were not randomly assigned to a treatment group: 16% were excluded from randomization because of the lack of a matched allogeneic donor; 11.6%, because of a lack of insurance authorization for autologous BMT; 10.4%, because of miscellaneous reasons. Of the 343 patients eligible for randomization, 110 (32%) chose to receive chemotherapy alone rather than participate in randomization. In all, 232 patients were randomly assigned to treatment groups: 117 to the group that received only intensive chemotherapy and 115 to the group that received autologous BMTs. Using an intent-to-treat principle of analysis, the researchers found no advantage for autologous BMT over intensive chemotherapy alone. 7 Primary contributors to the lack of success of autologous BMT were the relatively high rate of treatment regimen-related mortality (15% with autologous BMT vs 2.7% with intensive chemotherapy alone, P ¼ 0.05) and delayed bone marrow recovery after VP/AZ treatment during which AML in several patients relapsed; these relapses were counted as events in this intent-to-treat analysis.
The other important contributions of this study were detailed cytogenetic evaluation and the development of a partitioning model for risk-group identification based on clinical parameters and cytogenetic features (described in detail below).
Distinct results of POG 9421
The data collected from this study are undergoing evaluation. Preliminary analyses showed that no advantage was provided by high-dose DAT during induction therapy or by CsA during specific postinduction therapy. When the outcomes of all treatment groups were analyzed together, it was determined that patients receiving both experimental interventions (highdose DAT and CsA had a better EFS estimate than those treated with standard dose DAT induction therapy and no CsA (3 year EFS, 36.275 vs 22.774.2%; P ¼ 0.036). However, the P-value does not reach the level of statistical significance by a multiple testing procedure.
Risk factors
Starting with POG 8101, central review of morphology was required. Unlike BFM studies, POG studies have not separately recorded data indicating the presence or absence of Auer rods; therefore, it is not possible to use the BFM risk-group definitions to reclassify patients enrolled on POG studies. However, the availability of cytogenetic data from a large cohort of patients permitted POG researchers to develop risk-group definitions by using a partitioning analysis. Cytogenetic studies were not prospectively performed either POG8101 or 8498 studies and thus no data on cytogenetics are available on these two studies.
Complete cytogenetic data were available of 483 patients enrolled on POG 8821; the cohort was the largest ever from a single study of childhood AML. Normal karyotypes were observed in blast cells from 109 patients (22.6%); 11q23 abnormalities were seen in blast cells from 11.6% of patients; the t(8;21), in 11.8%; the t(15;17), in 11.4%, and the inv(16)/ t(16;16), in 6.0%. The group with an inv(16)/t(16;16) had the best 5-year OS estimate (68710.3%), and the groups with a normal karyotype or a t(8;21) had 5-year OS estimates of 50 and 46%, respectively. The reliability of cytogenetic data for prognosis in childhood AML was further confirmed by a more updated analysis of patients who were enrolled on POG 8821 and received chemotherapy alone (patients with Down's syndrome were excluded). The best EFS estimates were those of patients with an inv(16)/t (16;16) . Together with the OS findings cited above, the analysis suggested that, after relapse, salvage therapy is more effective in patients with an inv(16) than in those with other abnormalities. 10, 11 Partitioning analysis was prompted by the need to redefine prognostic markers in childhood AML because of the emerging practice of distinct treatment approaches for patients with APL and for those who have Down's syndrome and AML. A recursive partitioning analysis of patients treated on the POG 8821 study was conducted after data from children with Down's syndrome or APL were excluded. 9 After prognostic factors were identified by univariate analysis, a partitioning and amalgamation analysis was performed. Higher remission rates were seen for patients older than 2 years (P ¼ 0.026), for female patients (P ¼ 0.053), and for patients with an inv(16) or a t(8;21) (P ¼ 0.002). Conversely, lower remission rates were seen for patients with M5 subtypes of AML (P ¼ 0.028) and for patients with chromosome abnormalities other than an inv(16) and t(8;21) (P ¼ 0.047). When the prognostic variables and treatment variables were combined in the partitioning amalgamation analysis three groups of patients were shown to have different EFS probabilities. Female patients with an inv(16), a t(8;21), or normal chromosomes had the best outcome, and male patients with an inv(16), a t(8;21), or normal chromosomes had the second best outcome.
A second analysis of outcomes of patients (excluding those with APL or with Down's syndrome and AML and those undergoing BMT) enrolled on POG 8101, 8498, and 8821 indicated that the use of high-dose Ara-C in the second induction course resulted in a better outcome for patients in 8498 than in 8101; however, there was no significant difference between the outcomes seen in POG 8498 and 8821. This lack of difference indicates the large contribution of allogeneic BMT and Down's syndrome to the trend toward improved survival in successive childhood AML studies.
Results of children with Down's syndrome: Starting with the POG 8498 study, data from Down's syndrome patients with AML were analyzed separately from the data of other patients. As noted earlier, the 14 patients treated on POG 8498 remained disease-free. This high success rate of patients with Down's syndrome continued to be observed in POG 8821, although with the more intensified treatment, there were more deaths in remission: the EFS 5-year estimates in 8821 trial exceeded 66%. The outcome of Down's syndrome patients with AML is shown in Figure 7 .
Discussion
The results of the sequential POG studies described in the preceding sections demonstrated a stepwise increase in longterm survival as therapy was intensified. 3 The most striking change was seen in the POG 8101 study, in which a therapy consisting of anthracyclines and Ara-C resulted in a rate of remission induction and EFS estimates better than those resulting from the treatment originally designed for ALL. Three groups of patients seemed to have a superior outcome in later studies: those with Down's syndrome, 6 those with an inv(16), 9, 11 and those who were treated with matched-sibling BMT.
Despite intensification of remission induction therapy by the use of high-dose Ara-C during the second induction course in POG 8498 and POG 8821, the percentages of deaths due to toxicity during induction were low (4% in POG 8498 and 6% in POG 8821). The same trend was noted in POG 9421 in which additional intensification of therapy occurred with the use of high-dose Ara-C as part of the first remission induction course.
The 15-year OS estimates improved from 20% in the POG 8101 study to 40% in POG 8821. The same trends in OS and EFS were noted when the comparison was based on age: patients younger than 15 years fared better than those 15 years of age or older. Contributing factors to the improved survival estimates were the use of therapy specifically designed to treat AML; the use of more intensive postremission induction therapy, including the use of matched-sibling BMT; and improved supportive care. A review of dose intensification of Ara-C and daunorubicin across the four POG studies showed the pivotal contribution of Ara-C. The outcomes of groups that received chemotherapy only and did not include patients with Down's syndrome in the POG 8498 and 8821 studies were not significantly different, despite a doubling of the cumulative dose of daunorubicin in POG 8821 (average doses in POG 8498 and POG 8821, were 185 and 360 mg/m 2 , respectively) (Table 2 and Figure 6 ). It may very well be that the greatest contribution from anthracyclines occurs during the first course of induction therapy and that there is only a marginal contribution to OS by additional dose intensification of anthracyclines during postremission induction phases.
In general, improvements in outcome were observed in successive POG studies, but the OS and EFS estimates in the POG 8821 study are somewhat lower than those observed in the contemporary MRC 10 trial, 12 the BFM 87 trial, 13 and the Children's Cancer Group (CCG) 2891 study, in which an intensively timed Dexamethasone, cytarabine, thioguanine, etoposide, and rubidomycin (daunorubicin) (DCTER) regimen was tested.
14 The POG 8821 study used the standard 3 þ 7 þ 7 induction regimen of daunorubicin (total, 125 mg/m 2 ), Ara-C (total dose per course, 700 mg/m 2 ), and 6-TG (700 mg/m 2 ); the regimens in the BFM, MRC, and CCG studies used considerably greater total dose intensification of both daunorubicin (eg, 180 mg/m 2 in the BFM 87 and 150 mg/m 2 MRC 10 studies) and Ara-C (100 mg/m 2 twice a day for 10 days or a total of 2000 mg/m 2 in MRC 10,). Moreover, daunorubicin was administered as a bolus on days 1-3 in the POG studies, whereas it was given by continuous infusion in the DCTER regimen of CCG studies, as a split dose over 30 min twice a day on days 3-5 in the BFM studies and over 6 h on days 1, 3, and 5 in MRC 10. It is of interest that in vitro studies showed that at least 90 min of exposure to anthracyclines is required for their optimal intercalation into DNA. 15 However, the results of POG 8821 were superior to those resulting from the use of the standardtiming DCTER regimen of CCG 2891, in which the dose intensity during the first induction course was less than that used in POG 8821. These comparisons suggest that (1) a total daunorubicin dosage o100 mg/m 2 (such as that used in the CCG 2891 standard-timing regimen) is associated with a lower remission rate as well as lower EFS and OS estimates, (2) infusion of daunorubicin over 30 min or more yields results superior to those provided by bolus administration, (3) a total dose of Ara-C in excess of 1 g/m 2 or a total exposure period of 10 days yields results superior to those provided by the standard dose of 100 mg/m 2 administered daily for 7 days, and (4) highdose Ara-C given early after remission induction yields results superior to those resulting from treatment with standard-dose Ara-C.
In POG studies dose intensification of Ara-C either during induction or postremission phase was associated with improved results but not dose intensification of daunorubicin. Compared to POG 8101, significant dose intensification occurred in POG 8498, 8821 and 9421 with clear improvement in outcome. On the other hand despite a dose intensification of daunorubicin from 135 mg/M 2 in POG 8498 to 360 mg/M 2 in POG 8821 no significant improvement in outcome was evident when patients with Down's syndrome and those undergoing BMT were excluded. It is of note that, in vitro drug resistance studies show better correlation of cytotoxicity to Ara-C with risk for relapse in AML than cytotoxicity to daunorubicin. 16 The recent POG studies did not routinely give CNS radiation to any group of patients. Despite this lack of treatment, CNS disease was not the most frequent cause of relapse, even in patients with CNS disease at diagnosis. 10 A recent review noted better outcome in those with CNS disease at diagnosis; CNS disease at diagnosis is more common in those with good prognosis cytogenetics and this appears to account for the paradoxical outcome effect. 17 Figure 6 Event-free survival probabilities of patients who did not have Down's syndrome and did not undergo allogeneic bone marrow transplantation. These patients were enrolled on studies POG 8101, POG 8498, and POG 8821.
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The results of patients with Down's syndrome ( Figure 7 ) showed that the small cohort treated on POG 8498 had the best outcome. In subsequent studies the outcome was somewhat inferior, perhaps reflecting the increased toxicity from the considerable increases in anthracycline dose. In BFM studies with a higher dose intensity of anthracylines compared to POG 8498, there was a higher mortality among DS children compared to non-DS children 18 suggesting that reduction in treatment related mortality should be major goal in the therapy of DS children with AML. 19 The biochemical basis of the unique chemosensitivity of AML in Down's syndrome was studied by investigators POG and other groups [20] [21] [22] [23] and the reader is referred to some recent reviews on the subject. [24] [25] [26] In POG AML studies, for non-DS patients the best results were observed with allogeneic BMT. There was however a lack of any apparent benefit from autologous BMT in first CR in the multicenter randomized POG 8821 study. This was in large part due to the rather high treatment-related mortality (TRM) and as well from patients relapsing while waiting for autologous BMT, both of which were included as events in the intent to treat design of the study. 7 With longer observation there was no crossing over of the EFS curves, thus the negative impact of TRM was still evident. The results of POG 8821 are similar to the COG 2891 in this respect and as well with a large randomized adult AML study. 14, 27 On the other hand, at least three recent reports, albeit from nonrandomized studies, suggest that autologous BMT performed in first remission may improve the over all outcome in childhood AML, if the TRM could be reduced under 3%. [28] [29] [30] Thus, the question of when and whom to transplant in AML remains unsettled. 31, 32 Cytogenetic characteristics have emerged as the most important predictor of outcome in childhood AML in our studies and in others. After data of patients with Down's syndrome and with APL were excluded, the best outcome was observed for patients with an inv(16) þ t(16;16) with 5-year EFS of 60% and OS of 76% and the next best outcome was in patients with a t(8;21) or with a normal karyotype (see Table 3a and b). The remaining groups had the poorest outcomes. The EFS rates were lower for APL cases in part due to the requirement of evaluation of marrow response at day 14; as is now well recognized the kinetics of response in APL are quite different from other subgroups and often there is no aplasia at day 14; thus many of the patients removed because of high proportion of abnormal promyelocytes at day 14 on POG 8821 may have gone on to achieve CR at day 28. The same may have been the case for patients with 11q23 abnormalities who had a particularly poor outcome in POG8821 compared to other studies; the inclusion of etoposide in the first induction course as performed in CCG2891, BFM, MRC10, and the Nordic Society of Pediatric Hematology and Oncology (NOPHO) studies may also be important for this subgroup. 12, [33] [34] [35] In POG studies, subgroup analysis based on FAB classification was less reliable in a partioning model, presumably because of the overlap with cytogenetics which are straightforward. 9 As in the NOPHO studies, 36 the POG studies found that female sex is a predictor of good outcome after corrections for the cytogenetic results are made. 9, 36 Other prognostic parameters such as drug resistance, MDR1 expression and the role of further intensification of induction therapy are under evaluation, and we expect futures studies to provide additional information about prognosis and treatment. Additional contributing prognostic factors are pharmacogenomic differences in various populations under study. Overall survival probabilities of patients with Down's syndrome and AML enrolled on POG 8101, POG 8498, POG 8821, and POG 9421.
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